Bartlett & CO. Wealth Management LLC raised its holdings in Zoetis Inc. (NYSE:ZTS – Free Report) by 4.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 367,390 shares of the company’s stock after buying an additional 14,128 shares during the quarter. Bartlett & CO. Wealth Management LLC’s holdings in Zoetis were worth $57,295,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nova Wealth Management Inc. purchased a new stake in Zoetis in the first quarter valued at about $25,000. 1248 Management LLC purchased a new position in shares of Zoetis in the first quarter worth about $27,000. Saudi Central Bank purchased a new position in shares of Zoetis in the first quarter worth about $29,000. Cornerstone Planning Group LLC raised its stake in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after purchasing an additional 88 shares during the last quarter. Finally, ORG Partners LLC raised its stake in shares of Zoetis by 56.8% in the second quarter. ORG Partners LLC now owns 232 shares of the company’s stock worth $37,000 after purchasing an additional 84 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.
Zoetis Stock Up 2.1%
Shares of ZTS stock opened at $146.12 on Wednesday. The stock has a 50 day moving average of $150.16 and a 200 day moving average of $155.45. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock has a market cap of $64.76 billion, a P/E ratio of 25.15, a P/E/G ratio of 2.30 and a beta of 0.88. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $196.55.
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on ZTS shares. Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Argus restated a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Finally, Piper Sandler raised their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $200.88.
Get Our Latest Stock Report on Zoetis
Zoetis Company Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
See Also
- Five stocks we like better than Zoetis
- Why Are Stock Sectors Important to Successful Investing?
- PayPal Stock: Why Wall Street May Be Undervaluing This Giant
- What Do S&P 500 Stocks Tell Investors About the Market?
- Why Vertical Aerospace Could Lead the eVTOL Market by 2028
- Want to Profit on the Downtrend? Downtrends, Explained.
- Is Draganfly’s Army Partnership a Game-Changer for Investors?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.